We are focused on the development and commercialization of innovative therapeutics for the treatment of cancer.
| Preclinical | Clinical | Marketed | |||||
| Indication | Proof of Principle | Safety | Dose Optimization | Clinical Activity | Pivotal | Commercial | |
|---|---|---|---|---|---|---|---|
| Heme Malignancies | |||||||
| Emavusertib* IRAK4 |
IRAK4-driven Leukemia (AML/MDS) | TakeAim Leukemia | |||||
| Emavusertib* IRAK4 |
IRAK4-driven Lymphoma (NHL, CLL, WM) | TakeAim Lymphoma | |||||
| Fimepinostat HDAC/PI3K |
MYC-altered Cancers | ||||||
| Immune Checkpoint Inhibitors | |||||||
| CA-327* TIM3/PDL1 |
PDL1/TIM3-expressing Cancers | ||||||
| CA-170* VISTA/PDL1 |
PDL1/VISTA-expressing Cancers | ||||||
| Approved Drug | |||||||
| Erivedge** Hedgehog |
Basal Cell Carcinoma | ||||||
| Drug | Indication | Stage |
| Heme Malignancies | Emavusertib* IRAK4 |
IRAK4-driven Leukemia (AML/MDS) | Clinical Activity |
| Emavusertib* IRAK4 |
IRAK4-driven Lymphoma (NHL, CLL, WM) | Clinical Activity |
| Fimepinostat HDAC/PI3K |
MYC-altered Cancers | Clinical Activity |
| Immune Checkpoint Inhibitors | CA-327* TIM3/PDL1 |
PDL1/TIM3-expressing Cancers | Proof of Principle |
| CA-170* VISTA/PDL1 |
PDL1/VISTA-expressing Cancers | Clinical Activity |
| Approved Drug | Erivedge** Hedgehog |
Basal Cell Carcinoma | Commercial |
* IP licensed from Aurigene
** IP licensed to Genentech (Curis receives royalty income)
Indicates a program included in the Curis intellectual property portfolio, but not currently designated as a priority for clinical development.